Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice

被引：19
作者：
Litten, Raye Z. [1 ]
Falk, Daniel E. [1 ]
Ryan, Megan L. [1 ]
Fertig, Joanne [1 ]
Leggio, Lorenzo [2 ,3 ,4 ]
机构：
[1] NIAAA, Bethesda, MD USA
[2] NIAAA, Sect Clin Psychoneuroendocrinol & Neuropsychophar, NIH, Bethesda, MD USA
[3] NIDA, Medicat Dev Program, NIH, Baltimore, MD USA
[4] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA
来源：
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH | 2020年 / 44卷 / 01期
关键词：
Medications; Alcohol Use Disorder; Personalized Medicine; Targets; Screening Models; Medication Use; Health Services; Dissemination; PLACEBO-CONTROLLED TRIAL; ADDICTIONS NEUROCLINICAL ASSESSMENT; CELL-BASED MODELS; DOUBLE-BLIND; NALTREXONE RESPONSE; PRIMARY-CARE; DEPENDENT INDIVIDUALS; EXPRESSION SIGNATURES; RECEPTOR ANTAGONIST; PRECISION MEDICINE;
D O I：
10.1111/acer.14233
中图分类号：
R194 [卫生标准、卫生检查、医药管理];
学科分类号：
摘要：
引用
收藏
页码：23 / 35
页数：13
相关论文
共 50 条
  • [41] The combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial
    Yoon, Gihyun
    Sofuoglu, Mehmet
    Petrakis, Ismene L.
    Pittman, Brian
    Bell, Morris D.
    CONTEMPORARY CLINICAL TRIALS, 2024, 145
  • [42] Clinical dynamics of anhedonia symptom in mood disorder and in alcohol use disorder
    Roshchina, O.
    Simutkin, G.
    Bokhan, N.
    EUROPEAN PSYCHIATRY, 2021, 64 : S241 - S241
  • [43] Canadian Guideline for the Clinical Management of High-Risk Alcohol Consumption and Alcohol Use Disorder
    Wood, Evan
    Bright, Jessica
    Hsu, Katrina
    Goel, Nirupa
    Ross, Josey W. G.
    Hanson, Averill
    Teed, Rand
    Poulin, Ginette
    Denning, Bryany
    Corace, Kim
    Chase, Corrina
    Halpape, Katelyn
    Lim, Ronald
    Kealey, Tim
    Rehm, Juergen
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (09) : E303 - E321
  • [44] Influences on advance practice nursing education to prescribe medications for opioid use disorder
    Phoenix, Bethany J.
    Tierney, Matthew
    Chapman, Susan A.
    Spetz, Joanne
    NURSING OUTLOOK, 2023, 71 (03)
  • [45] Practical Assessment of Alcohol Use Disorder in Routine Primary Care: Performance of an Alcohol Symptom Checklist
    Kevin A. Hallgren
    Theresa E. Matson
    Malia Oliver
    Katie Witkiewitz
    Jennifer F. Bobb
    Amy K. Lee
    Ryan M. Caldeiro
    Daniel Kivlahan
    Katharine A. Bradley
    Journal of General Internal Medicine, 2022, 37 : 1885 - 1893
  • [46] Practical Assessment of Alcohol Use Disorder in Routine Primary Care: Performance of an Alcohol Symptom Checklist
    Hallgren, Kevin A.
    Matson, Theresa E.
    Oliver, Malia
    Witkiewitz, Katie
    Bobb, Jennifer F.
    Lee, Amy K.
    Caldeiro, Ryan M.
    Kivlahan, Daniel
    Bradley, Katharine A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (08) : 1885 - 1893
  • [47] Medications for Alcohol Use Disorders in a Primary Care Practice-Based Research Network Implementation Study
    Wessell, Andrea M.
    Nemeth, Lynne S.
    Jenkins, Ruth G.
    Ornstein, Steven M.
    Miller, Peter M.
    ALCOHOLISM TREATMENT QUARTERLY, 2014, 32 (01) : 58 - 66
  • [48] Insomnia medications: History, characteristics, and guidelines for optimal use in clinical practice
    Krystal, Andrew D.
    JOURNAL OF SLEEP RESEARCH, 2023, 32 (06)
  • [49] GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence
    Agabio, Roberta
    Colombo, Giancarlo
    FRONTIERS IN NEUROSCIENCE, 2014, 8
  • [50] N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial
    Back, Sudie E.
    Gray, Kevin
    Santa Ana, Elizabeth
    Jones, Jennifer L.
    Jarnecke, Amber M.
    Joseph, Jane E.
    Prisciandaro, James
    Killeen, Therese
    Brown, Delisa G.
    Taimina, Linda
    Compean, Ebele
    Malcolm, Robert
    Flanagan, Julianne C.
    Kalivas, Peter W.
    CONTEMPORARY CLINICAL TRIALS, 2020, 91
12345